Cargando…

Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia

Background: Hepatocellular carcinoma (HCC) rarely develops in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR). We assessed the incidence of HCC in CHC patients with hemophilia after treatment with pegylated interferon plus ribavirin (PegIFN/RBV) and direct-ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, In Jung, Yoo, Sung Hwan, Kim, Sora, Cho, Young Youn, Yoo, Ki Young, Kim, Hyung Joon, Lee, Hyun Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911386/
https://www.ncbi.nlm.nih.gov/pubmed/35268541
http://dx.doi.org/10.3390/jcm11051451
_version_ 1784666789278384128
author Kim, In Jung
Yoo, Sung Hwan
Kim, Sora
Cho, Young Youn
Yoo, Ki Young
Kim, Hyung Joon
Lee, Hyun Woong
author_facet Kim, In Jung
Yoo, Sung Hwan
Kim, Sora
Cho, Young Youn
Yoo, Ki Young
Kim, Hyung Joon
Lee, Hyun Woong
author_sort Kim, In Jung
collection PubMed
description Background: Hepatocellular carcinoma (HCC) rarely develops in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR). We assessed the incidence of HCC in CHC patients with hemophilia after treatment with pegylated interferon plus ribavirin (PegIFN/RBV) and direct-acting antivirals (DAAs). Methods: Patients (n = 202) were enrolled between March 2007 and July 2019. A total of 139 patients were treated with PegIFN/RBV (genotype 1, n = 98; genotype 2, n = 41). Sixty-three patients were treated with DAAs (genotype 1, n = 44; genotype 2, n = 19). The cumulative incidence rates of HCC were estimated using the Kaplan–Meier method and compared using the log-rank test. Results: For genotype 1, SVR was achieved in 78.6% (77/98) and 90.9% (40/44) of patients in the PegIFN/RBV and DAAs groups, respectively. For genotype 2, SVR was achieved in 95.1% (39/41) and 94.7% (18/19) of patients in the PegIFN/RBV and DAAs groups, respectively. Six HCC cases were identified. The cumulative incidence of HCC was 4.1% at 14 years in PegIFN/RBV and 1.7% at 5 years in DAAs. The 14-year cumulative incidence of HCC was 1.9% in the SVR group and 21.7% in the no-SVR group in the PegIFN/RBV group (p < 0.001). Conclusions: Treatment with PegIFN/RBV led to stable SVR and a low incidence of HCC. Although the follow-up period was short, DAAs led to more stable SVR than PegIFN/RBV and a low incidence of HCC in CHC patients with hemophilia.
format Online
Article
Text
id pubmed-8911386
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89113862022-03-11 Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia Kim, In Jung Yoo, Sung Hwan Kim, Sora Cho, Young Youn Yoo, Ki Young Kim, Hyung Joon Lee, Hyun Woong J Clin Med Article Background: Hepatocellular carcinoma (HCC) rarely develops in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR). We assessed the incidence of HCC in CHC patients with hemophilia after treatment with pegylated interferon plus ribavirin (PegIFN/RBV) and direct-acting antivirals (DAAs). Methods: Patients (n = 202) were enrolled between March 2007 and July 2019. A total of 139 patients were treated with PegIFN/RBV (genotype 1, n = 98; genotype 2, n = 41). Sixty-three patients were treated with DAAs (genotype 1, n = 44; genotype 2, n = 19). The cumulative incidence rates of HCC were estimated using the Kaplan–Meier method and compared using the log-rank test. Results: For genotype 1, SVR was achieved in 78.6% (77/98) and 90.9% (40/44) of patients in the PegIFN/RBV and DAAs groups, respectively. For genotype 2, SVR was achieved in 95.1% (39/41) and 94.7% (18/19) of patients in the PegIFN/RBV and DAAs groups, respectively. Six HCC cases were identified. The cumulative incidence of HCC was 4.1% at 14 years in PegIFN/RBV and 1.7% at 5 years in DAAs. The 14-year cumulative incidence of HCC was 1.9% in the SVR group and 21.7% in the no-SVR group in the PegIFN/RBV group (p < 0.001). Conclusions: Treatment with PegIFN/RBV led to stable SVR and a low incidence of HCC. Although the follow-up period was short, DAAs led to more stable SVR than PegIFN/RBV and a low incidence of HCC in CHC patients with hemophilia. MDPI 2022-03-07 /pmc/articles/PMC8911386/ /pubmed/35268541 http://dx.doi.org/10.3390/jcm11051451 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, In Jung
Yoo, Sung Hwan
Kim, Sora
Cho, Young Youn
Yoo, Ki Young
Kim, Hyung Joon
Lee, Hyun Woong
Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
title Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
title_full Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
title_fullStr Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
title_full_unstemmed Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
title_short Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
title_sort low incidence of hepatocellular carcinoma after antiviral therapy in patients with chronic hepatitis c and hemophilia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911386/
https://www.ncbi.nlm.nih.gov/pubmed/35268541
http://dx.doi.org/10.3390/jcm11051451
work_keys_str_mv AT kiminjung lowincidenceofhepatocellularcarcinomaafterantiviraltherapyinpatientswithchronichepatitiscandhemophilia
AT yoosunghwan lowincidenceofhepatocellularcarcinomaafterantiviraltherapyinpatientswithchronichepatitiscandhemophilia
AT kimsora lowincidenceofhepatocellularcarcinomaafterantiviraltherapyinpatientswithchronichepatitiscandhemophilia
AT choyoungyoun lowincidenceofhepatocellularcarcinomaafterantiviraltherapyinpatientswithchronichepatitiscandhemophilia
AT yookiyoung lowincidenceofhepatocellularcarcinomaafterantiviraltherapyinpatientswithchronichepatitiscandhemophilia
AT kimhyungjoon lowincidenceofhepatocellularcarcinomaafterantiviraltherapyinpatientswithchronichepatitiscandhemophilia
AT leehyunwoong lowincidenceofhepatocellularcarcinomaafterantiviraltherapyinpatientswithchronichepatitiscandhemophilia